AstraZeneca reports Tagrisso-Orpathys combo could prolong treatment for EGFR-mutant lung cancer

At the European Society for Medical Oncology meeting, AstraZeneca said early data suggest that adding Orpathys to Tagrisso may let patients with mutant non‑small cell lung cancer continue therapy after developing resistance to the EGFR‑targeting tyrosine kinase inhibitor.

The company explained that the two‑pill regimen is designed to address the common mechanisms that cause loss of response to Tagrisso, potentially extending the drug's clinical benefit.

No regulatory approval has been announced, and the findings are based on preliminary observations presented at the conference. AstraZeneca indicated further clinical evaluation will be needed to confirm the benefit.

If validated, the approach could provide an additional option for clinicians managing EGFR‑mutant lung cancer, a disease where treatment options become limited after resistance develops.